Review





Similar Products

99
NSJ Bioreagents cd1a antibody
Cd1a Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd1a antibody/product/NSJ Bioreagents
Average 99 stars, based on 1 article reviews
cd1a antibody - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

94
Novus Biologicals primary monoclonal antibodies against cd1a
Primary Monoclonal Antibodies Against Cd1a, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary monoclonal antibodies against cd1a/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
primary monoclonal antibodies against cd1a - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Elabscience Biotechnology cell suspension
Cell Suspension, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell suspension/product/Elabscience Biotechnology
Average 94 stars, based on 1 article reviews
cell suspension - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Elabscience Biotechnology apc anti human cd1a antibody
Flow cytometric analysis of <t>CD1a</t> and CD83 expression on the surface of DCs at different time points. (A) Expression of CDla on Day 1 of Culture; (B) Expression of CDla on Day 8 of Culture; (C) Statistical Analysis Results of CDla on Day 1 and Day 8 of Culture; (D) Expression of CD83 on Day 1 of Culture; (E) Expression of CD83 on Day 8 of Culture; (F) Statistical Analysis Results of CD83 on Day 1 and Day 8 of Culture. It is evident that the maturation rate of DCs induced by GM-CSF and IL-4 has been significantly enhanced, thereby facilitating sample preparation for subsequent experiments.Statistical significance is indicated in the figure (*p < 0.05, **P < 0.01, ***P < 0.001).
Apc Anti Human Cd1a Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc anti human cd1a antibody/product/Elabscience Biotechnology
Average 94 stars, based on 1 article reviews
apc anti human cd1a antibody - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

86
Cell Marque cd1a
Posttreatment TME changes and cytokine enrichment in responders and nonresponders. A, Heatmap displaying transcriptomic profiles from posttreatment RNA-seq, illustrating changes in key TME features, including angiogenesis, immune infiltration, and EMT signatures. B, Sankey diagram showing shifts in TME classification from baseline (Pre) to posttreatment (Post) in responders and nonresponders, highlighting transitions between IE, IE-F, F, and depleted (D) phenotypes. C and D, NES for hallmark cytokine pathways (IFNα, IFNγ, TNFα, and TGFβ) in bulk RNA and spatial compartments PanCKe, CD163e, and CD45e, comparing baseline vs. posttreatment samples in responders ( C ) and nonresponders ( D ). Statistically significant differences ( P < 0.05) are indicated by gray bars. E, Box plot showing the percent expression of <t>CD1a</t> at baseline between responders and nonresponders. Quantification of CD1a staining is based on percent CD1a-positive cells in three regions per sample ( n = 15 responders; n = 12 nonresponders), with responders exhibiting a 2.25-fold higher average CD1a expression compared with nonresponders (*, P = 0.0294). F, Box plot showing the mean distances between CD8 + and FOXP3+ cells at baseline in responders and nonresponders. No statistically significant difference was observed (*, P = 0.74). G, Representative CD1a IHC staining images from a baseline responder (left) and nonresponder (right) biopsy sample. Scale bar, 50 microns. NR, nonresponder; Pre R, baseline responders; R, nonresponder. (Created with BioRender.com. Llerena, P., and Samarah, H. [2025] https://BioRender.com/nf4luru .)
Cd1a, supplied by Cell Marque, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd1a/product/Cell Marque
Average 86 stars, based on 1 article reviews
cd1a - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

93
fluidigm 3167012b
Posttreatment TME changes and cytokine enrichment in responders and nonresponders. A, Heatmap displaying transcriptomic profiles from posttreatment RNA-seq, illustrating changes in key TME features, including angiogenesis, immune infiltration, and EMT signatures. B, Sankey diagram showing shifts in TME classification from baseline (Pre) to posttreatment (Post) in responders and nonresponders, highlighting transitions between IE, IE-F, F, and depleted (D) phenotypes. C and D, NES for hallmark cytokine pathways (IFNα, IFNγ, TNFα, and TGFβ) in bulk RNA and spatial compartments PanCKe, CD163e, and CD45e, comparing baseline vs. posttreatment samples in responders ( C ) and nonresponders ( D ). Statistically significant differences ( P < 0.05) are indicated by gray bars. E, Box plot showing the percent expression of <t>CD1a</t> at baseline between responders and nonresponders. Quantification of CD1a staining is based on percent CD1a-positive cells in three regions per sample ( n = 15 responders; n = 12 nonresponders), with responders exhibiting a 2.25-fold higher average CD1a expression compared with nonresponders (*, P = 0.0294). F, Box plot showing the mean distances between CD8 + and FOXP3+ cells at baseline in responders and nonresponders. No statistically significant difference was observed (*, P = 0.74). G, Representative CD1a IHC staining images from a baseline responder (left) and nonresponder (right) biopsy sample. Scale bar, 50 microns. NR, nonresponder; Pre R, baseline responders; R, nonresponder. (Created with BioRender.com. Llerena, P., and Samarah, H. [2025] https://BioRender.com/nf4luru .)
3167012b, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3167012b/product/fluidigm
Average 93 stars, based on 1 article reviews
3167012b - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Novus Biologicals af488 anti cd1a
Posttreatment TME changes and cytokine enrichment in responders and nonresponders. A, Heatmap displaying transcriptomic profiles from posttreatment RNA-seq, illustrating changes in key TME features, including angiogenesis, immune infiltration, and EMT signatures. B, Sankey diagram showing shifts in TME classification from baseline (Pre) to posttreatment (Post) in responders and nonresponders, highlighting transitions between IE, IE-F, F, and depleted (D) phenotypes. C and D, NES for hallmark cytokine pathways (IFNα, IFNγ, TNFα, and TGFβ) in bulk RNA and spatial compartments PanCKe, CD163e, and CD45e, comparing baseline vs. posttreatment samples in responders ( C ) and nonresponders ( D ). Statistically significant differences ( P < 0.05) are indicated by gray bars. E, Box plot showing the percent expression of <t>CD1a</t> at baseline between responders and nonresponders. Quantification of CD1a staining is based on percent CD1a-positive cells in three regions per sample ( n = 15 responders; n = 12 nonresponders), with responders exhibiting a 2.25-fold higher average CD1a expression compared with nonresponders (*, P = 0.0294). F, Box plot showing the mean distances between CD8 + and FOXP3+ cells at baseline in responders and nonresponders. No statistically significant difference was observed (*, P = 0.74). G, Representative CD1a IHC staining images from a baseline responder (left) and nonresponder (right) biopsy sample. Scale bar, 50 microns. NR, nonresponder; Pre R, baseline responders; R, nonresponder. (Created with BioRender.com. Llerena, P., and Samarah, H. [2025] https://BioRender.com/nf4luru .)
Af488 Anti Cd1a, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/af488 anti cd1a/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
af488 anti cd1a - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


Flow cytometric analysis of CD1a and CD83 expression on the surface of DCs at different time points. (A) Expression of CDla on Day 1 of Culture; (B) Expression of CDla on Day 8 of Culture; (C) Statistical Analysis Results of CDla on Day 1 and Day 8 of Culture; (D) Expression of CD83 on Day 1 of Culture; (E) Expression of CD83 on Day 8 of Culture; (F) Statistical Analysis Results of CD83 on Day 1 and Day 8 of Culture. It is evident that the maturation rate of DCs induced by GM-CSF and IL-4 has been significantly enhanced, thereby facilitating sample preparation for subsequent experiments.Statistical significance is indicated in the figure (*p < 0.05, **P < 0.01, ***P < 0.001).

Journal: Frontiers in Molecular Biosciences

Article Title: Deciphering the circRNA-Mediated ceRNA regulatory network in dendritic cells during H37Ra and BCG infection

doi: 10.3389/fmolb.2026.1764518

Figure Lengend Snippet: Flow cytometric analysis of CD1a and CD83 expression on the surface of DCs at different time points. (A) Expression of CDla on Day 1 of Culture; (B) Expression of CDla on Day 8 of Culture; (C) Statistical Analysis Results of CDla on Day 1 and Day 8 of Culture; (D) Expression of CD83 on Day 1 of Culture; (E) Expression of CD83 on Day 8 of Culture; (F) Statistical Analysis Results of CD83 on Day 1 and Day 8 of Culture. It is evident that the maturation rate of DCs induced by GM-CSF and IL-4 has been significantly enhanced, thereby facilitating sample preparation for subsequent experiments.Statistical significance is indicated in the figure (*p < 0.05, **P < 0.01, ***P < 0.001).

Article Snippet: Subsequently, 100 μL of the cell suspension was separately incubated with 5 μL of APC Anti-Human CD1a Antibody and PE Anti-Human CD83 Antibody 5 μL of antibodies (Elabscience Biotechnology Co., Ltd., Wuhan, China).The samples were mixed thoroughly and incubated for 30 min at room temperature in the dark.

Techniques: Expressing, Sample Prep

Posttreatment TME changes and cytokine enrichment in responders and nonresponders. A, Heatmap displaying transcriptomic profiles from posttreatment RNA-seq, illustrating changes in key TME features, including angiogenesis, immune infiltration, and EMT signatures. B, Sankey diagram showing shifts in TME classification from baseline (Pre) to posttreatment (Post) in responders and nonresponders, highlighting transitions between IE, IE-F, F, and depleted (D) phenotypes. C and D, NES for hallmark cytokine pathways (IFNα, IFNγ, TNFα, and TGFβ) in bulk RNA and spatial compartments PanCKe, CD163e, and CD45e, comparing baseline vs. posttreatment samples in responders ( C ) and nonresponders ( D ). Statistically significant differences ( P < 0.05) are indicated by gray bars. E, Box plot showing the percent expression of CD1a at baseline between responders and nonresponders. Quantification of CD1a staining is based on percent CD1a-positive cells in three regions per sample ( n = 15 responders; n = 12 nonresponders), with responders exhibiting a 2.25-fold higher average CD1a expression compared with nonresponders (*, P = 0.0294). F, Box plot showing the mean distances between CD8 + and FOXP3+ cells at baseline in responders and nonresponders. No statistically significant difference was observed (*, P = 0.74). G, Representative CD1a IHC staining images from a baseline responder (left) and nonresponder (right) biopsy sample. Scale bar, 50 microns. NR, nonresponder; Pre R, baseline responders; R, nonresponder. (Created with BioRender.com. Llerena, P., and Samarah, H. [2025] https://BioRender.com/nf4luru .)

Journal: Clinical Cancer Research

Article Title: Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC

doi: 10.1158/1078-0432.CCR-25-1098

Figure Lengend Snippet: Posttreatment TME changes and cytokine enrichment in responders and nonresponders. A, Heatmap displaying transcriptomic profiles from posttreatment RNA-seq, illustrating changes in key TME features, including angiogenesis, immune infiltration, and EMT signatures. B, Sankey diagram showing shifts in TME classification from baseline (Pre) to posttreatment (Post) in responders and nonresponders, highlighting transitions between IE, IE-F, F, and depleted (D) phenotypes. C and D, NES for hallmark cytokine pathways (IFNα, IFNγ, TNFα, and TGFβ) in bulk RNA and spatial compartments PanCKe, CD163e, and CD45e, comparing baseline vs. posttreatment samples in responders ( C ) and nonresponders ( D ). Statistically significant differences ( P < 0.05) are indicated by gray bars. E, Box plot showing the percent expression of CD1a at baseline between responders and nonresponders. Quantification of CD1a staining is based on percent CD1a-positive cells in three regions per sample ( n = 15 responders; n = 12 nonresponders), with responders exhibiting a 2.25-fold higher average CD1a expression compared with nonresponders (*, P = 0.0294). F, Box plot showing the mean distances between CD8 + and FOXP3+ cells at baseline in responders and nonresponders. No statistically significant difference was observed (*, P = 0.74). G, Representative CD1a IHC staining images from a baseline responder (left) and nonresponder (right) biopsy sample. Scale bar, 50 microns. NR, nonresponder; Pre R, baseline responders; R, nonresponder. (Created with BioRender.com. Llerena, P., and Samarah, H. [2025] https://BioRender.com/nf4luru .)

Article Snippet: Paraffin sections of pretreatment biopsies from the same subjects used for bulk RNA-seq analyses (five responders; four nonresponders) were stained with antibody to CD1a, Langerhans’s cell marker (Cell Marque 101R-14, Sigma) using a three-step avidin–biotin method.

Techniques: RNA Sequencing, Expressing, Staining, Immunohistochemistry